• Publications
  • Influence
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
The large between-group differences on negative symptoms, hostility/excitement, and anxiety/depression suggest that risperidone and other serotonin/dopamine antagonists have qualitatively different effects from those of conventional antipsychotic agents.
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
It is suggested that risperidone, at the optimal therapeutic dose of 6 mg/day, produced significant improvement in both positive and negative symptoms without an increase in drug-induced parkinsonian symptoms and with a significant beneficial effect on tardive dyskinesia.
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
  • G. Chouinard
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1 March 2004
Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome.
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
Results support the safety and efficacy of daily dosages of 50, 100, and 200 mg of sertraline in the short-term treatment of patients with OCD.
Neuroleptic-induced supersensitivity psychosis.
The anticholinergic effects of chlorpromazine, amitriptyline, scopolamine (Sominex) (0), and tropicamide were probably additive and although her disorientation cleared rapidly, Ms. A maintained that her hallucinations persisted during her 2-week hospitalization.
Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial
Treatment with risperidone was accompanied by an improvement in global functioning in patients with average to above-average impairment at baseline as measured by the Global Assessment of Functioning scale, and hypokinesia and tremor increased in the ris peridone group, but the effect on tremor was largely confined to subjects with higher baseline tremor scores.